Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 27

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 27
---
 of 2025, compared to $69 million in the second quarter of 2024, an increase of $52 million or 75%.

#### Reimbursement Revenue
Reimbursement revenue amounted to $13 million in the second quarter of 2025 compared to $42 million in the second quarter of 2024, a decrease of $29 million or 69%.

Cost of Product Sales Genmab recognized cost of product sales of $99 million in the first six months of 2025 compared to $55 million in the first six months of 2024. Cost of product sales includes product costs and profit-sharing amounts payable to AbbVie related to EPKINLY of $82 million.

Key Developments to Cost of Product Sales – Second Quarter of 2025

Cost of product sales were $57 million for the second quarter of 2025 compared to $28 million for the second quarter of 2024. Cost of product sales includes product costs and profit-sharing amounts payable to AbbVie related to EPKINLY of $47 million.

Research and Development Expenses Research and development expenses amounted to $723 million in the first six months of 2025 compared to $696 million in the first six months of 2024. The increase of $27 million, or 4%, was driven by the addition of ProfoundBio related research and development expenses, primarily Rina-S, and the increase in team members to support the continued expansion of our product portfolio. The acquisition of ProfoundBio occurred in the second quarter of 2024 and therefore there were minimal ProfoundBio related research and development expenses during the first six months of 2024. These increases were partly offset by decreased research and development expenses related to Epcoritamab under our collaboration with AbbVie, primarily due to the program’s shift towards less costly label expansion and post-marketing studies in the first six months of 2025 compared to later-stage development activities in the first six months of 2024.

Research and development expenses accounted for 73% of total research and development expenses & selling, general and administrative expenses in the first six months of 2025 compared to 74% in the first six months of 2024.

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 18/44